- LuxSit™ Pro is the first
fully de novo protein to enter the commercial market
SEATTLE, July 15,
2024 /PRNewswire/ -- Monod Bio, a life sciences
company using AI to generate new proteins for the research use only
(RUO) and in vitro diagnostics (IVD) markets, announced today the
launch of the LuxSit™ Pro family of products, the world's smallest
and first commercially-available de novo luciferases, which are
light-emitting enzymes that use proprietary chemical substrates.
The products are initially available in two formats: as a whole
protein reporter, and as a split-pair for studying protein-protein
interactions.
With its design and performance, LuxSit™
Pro will empower researchers with a toolset suited for research and
diagnostic applications.
The LuxSit™ Pro family of products is biochemically optimized
for stability and brightness. Overall performance has been improved
more than 150-fold from its academic predecessor LuxSit.
Key features of the new LuxSit™ Pro products include 1) enhanced
brightness and an extended linear range for robust assay
performance, 2) a small, hyperstable protein structure for ease of
use, storage and versatility, and 3) high specificity to the
Company's proprietary synthetic substrates, ensuring assay
reliability and consistency.
Daniel-Adriano Silva, Ph.D., CEO
and co-founder Monod Bio, said, "We're excited to launch LuxSit™
Pro for the research community. To our knowledge, this is the first
time a de novo protein has reached the commercial market. With its
design and performance, LuxSit™ Pro will empower researchers with a
toolset suited for research and diagnostic applications."
Alfredo-Quijano Rubio, Ph.D., CSO
and co-founder of Monod Bio, said, "LuxSit™ Pro establishes a new
benchmark in stability and sensitivity. We believe this reporter
will allow researchers across the life sciences to meaningfully
advance their research."
David Baker, a Howard Hughes
Medical Institute investigator and professor of biochemistry at UW
Medicine and co-founder of Monod Bio, said, "This is a real
milestone for biology and computer science, and I am confident we
will soon see many more de novo designed proteins mature into
commercial products in the months and years ahead." Baker is the
director of the Institute for Protein Design at UW Medicine where
the LuxSit technology was initially developed.
LuxSit™ Pro is a tool for basic research and diagnostic
innovation. It is available in adaptable formats tailored for a
spectrum of applications, spanning comprehensive protein reporting
to unraveling intricate protein-protein interactions.
In addition to LuxSit™, Monod Bio is also developing de novo
protein binders and novel protein biosensors, further expanding the
possibilities in protein engineering and diagnostics. These
innovations underscore the Company's commitment to developing and
commercializing de novo protein products.
For more information about purchasing LuxSit™ Pro please visit
https://monod.bio/access-luxsit-pro/.
About LuxSit
LuxSit™ Pro is a versatile luciferase enzyme available in both
whole-enzyme and split-enzyme formats. LuxSit™ Pro has optimized
brightness and glow time for in vitro assays, making it suitable
for a wide range of applications in research and diagnostics. Its
small size and hyperstability further enhance its usability, while
its specificity to the Company's proprietary synthetic substrate
helps prioritize reliable and consistent results. For more
information, visit https://monod.bio/technology/.
About Monod Bio
Monod Bio is a spinout company from the University of Washington developing de novo
protein-based products for the RUO and IVD commercial markets. The
Company's biosensor platform harnesses the power of computational
de novo protein design and facilitates swift, highly sensitive
analytical assays. Founded on technology developed in the
laboratory of HHMI investigator and UW Medicine professor
David Baker, Monod Bio is the first
company to commercialize a product based on a fully de novo
protein. The Company's research has been published in several
peer-reviewed journals, including Nature and Nature
Biotechnology. Monod Bio is based in Seattle, WA. For more information, visit
www.monodbio.com.
Media Contact
Monod Bio
David Shoultz, PhD, MBA
Chief Operating Officer & Co-Founder
dshoultz@monod.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/monod-bio-launches-worlds-first-fully-de-novo-protein-product-luciferase-luxsit-pro-for-life-sciences-research-and-diagnostics-302197158.html
SOURCE Monod Bio, Inc.